Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases

Inclusion Criteria: 1. Prostate cancer confirmed by pathological findings; 2. Bone metastasis confirmed by bone scan, the number of bone metastases ≤10 3. Agreement to undergo laparoscopic radical prostatectomy + pelvic lymphadenectomy; 4. ECOG score of 0 - 1 5. Agreement to undergo preoperative and postoperative endocrine therapy and 89Sr radionuclide therapy; 6. Voluntary signing of an ICF for the clinical trial Exclusion Criteria: 1. Any other tumor disease requiring treatment; 2. Any organ metastasis confirmed by imaging, such as liver and brain metastases, or the possibility of paralysis due to spinal cord metastasis; 3. A history of epilepsy or any condition that may lead to seizures; 4. Severe liver or kidney dysfunction, severe cardiovascular or cerebrovascular diseases, and systemic immune system diseases